Treatment of canine Old World visceral leishmaniasis: a systematic review

DOI: 10.1111/j.1365-3164.2005.00460.x
Veterinary Dermatology, 2005, 16, 213-32.

#	Paper	IF	Citations
125	Canine leishmaniasis - a new danger for British dogs: How to recognize and treat it. **2006**, 11, 66-70		
124	Deltamethrin-impregnated collars for the control of canine leishmaniasis: evaluation of the protective effect and influence on the clinical outcome of Leishmania infection in kennelled stray dogs. **2006**, 142, 142-5		72
123	Canine leishmaniasis chemotherapy: dog's clinical condition and risk of Leishmania transmission. **2006**, 53, 540-5		14
122	Immunogenicity of a killed Leishmania vaccine with saponin adjuvant in dogs. **2007**, 25, 7674-86		55
121	Sporotrichosis: the main differential diagnosis with tegumentary leishmaniosis in dogs from Rio de Janeiro, Brazil. **2007**, 143, 1-6		16
120	In vitro activity of dicationic compounds against a North American foxhound isolate of Leishmania infantum. **2007**, 145, 207-16		11
119	Nodular lesions of the tongue in canine leishmaniosis. **2007**, 54, 414-7		18
118	Setting new immunobiological parameters in the hamster model of visceral leishmaniasis for in vivo testing of antileishmanial compounds. **2007**, 31, 703-17		22
117	HPLC assay for determination of amphotericin B in biological samples. **2008**, 22, 402-7		25
116	Efficacy of different treatment regimens of marbofloxacin in canine visceral leishmaniosis: a pilot study. **2008**, 153, 244-54		14
115	Canine leishmaniosis--new concepts and insights on an expanding zoonosis: part two. **2008**, 24, 371-7		175
114	Canine leishmaniasis: a diagnostic and clinical challenge. **2008**, 175, 14-5		46
113	Antigenicity of a whole parasite vaccine as promising candidate against canine leishmaniasis. **2008**, 85, 106-12		30
112	A killed Leishmania vaccine with sand fly saliva extract and saponin adjuvant displays immunogenicity in dogs. **2008**, 26, 623-38		41
111	Despite Leishvaccine and Leishmune trigger distinct immune profiles, their ability to activate phagocytes and CD8+ T-cells support their high-quality immunogenic potential against canine visceral leishmaniasis. **2008**, 26, 2211-24		28
110	Kinetics of cell migration to the dermis and hypodermis in dogs vaccinated with antigenic compounds of Leishmania braziliensis plus saponin. **2008**, 26, 3922-31		10
109	Reduced tissue parasitic load and infectivity to sand flies in dogs naturally infected by Leishmania (Leishmania) chagasi following treatment with a liposome formulation of meglumine antimoniate. **2008**, 52, 2564-72		64

108	Visceral leishmaniasis in large Brazilian cities: challenges for control. **2008**, 24, 2953-8		40
107	Use of domperidone in the treatment of canine visceral leishmaniasis: a clinical trial. **2009**, 179, 259-63		44
106	Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis. *Parasitology Research*, **2009**, 105, 155-62	2.4	41
105	Clinical efficacy and tolerance of miltefosine in the treatment of canine leishmaniosis. *Parasitology Research*, **2009**, 105, 463-9	2.4	31
104	Evidence-based veterinary dermatology: a systematic review of interventions for Malassezia dermatitis in dogs. *Veterinary Dermatology*, **2009**, 20, 1-12	1.8	68
103	Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis. *Veterinary Dermatology*, **2009**, 20, 397-404	1.8	73
102	Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniosis. **2009**, 165, 1-18		381
101	Administration of miltefosine and meglumine antimoniate in healthy dogs: clinicopathological evaluation of the impact on the kidneys. **2009**, 37, 770-5		37
100	Systemic and compartmentalized immune response in canine visceral leishmaniasis. **2009**, 128, 87-95		127
99	Determination of CD4+ and CD8+ T cells in the peripheral blood of dogs with leishmaniosis before and after prolonged allopurinol monotherapy. **2010**, 186, 262-3		11
98	Clinical and laboratory monitoring of dogs naturally infected by Leishmania infantum. **2010**, 186, 370-3		23
97	Some remarks about the LeishVet directions for the treatment of canine leishmaniasis. **2010**, 169, 416-7; author reply 418-20		0
96	Response to the letter: Some remarks about the LeishVet directions for the treatment of canine leishmaniosis **2010**, 169, 418-420		
95	Dynamics and predictive potential of antibodies against insect-derived recombinant Leishmania infantum proteins during chemotherapy of naturally infected dogs. *American Journal of Tropical Medicine and Hygiene*, **2010**, 82, 795-800	3.2	7
94	Update on the diagnosis and management of Leishmania spp infections in dogs in the United States. **2010**, 25, 149-54		8
93	Dogs with Leishmania chagasi infection have semen abnormalities that partially revert during 150 days of Allopurinol and Amphotericin B therapy. **2010**, 117, 183-6		14
92	New delivery strategies for the old pentavalent antimonial drugs. **2010**, 7, 1343-58		64
91	Immunological changes in canine peripheral blood leukocytes triggered by immunization with first or second generation vaccines against canine visceral leishmaniasis. **2011**, 141, 64-75		22

90	First report of the use of meglumine antimoniate for treatment of canine leishmaniasis in a pregnant dog. **2011**, 47, 67-71		3
89	Long term follow-up of dogs diagnosed with leishmaniosis (clinical stage II) and treated with meglumine antimoniate and allopurinol. **2011**, 188, 346-51		50
88	Efficacy of Staphylococcus aureus vaccines for bovine mastitis: a systematic review. **2011**, 148, 117-24		79
87	Canine leishmaniasis: the key points for qPCR result interpretation. *Parasites and Vectors*, **2011**, 4, 57	4	49
86	Infectivity to Phlebotomus perniciosus of dogs naturally parasitized with Leishmania infantum after different treatments. *Parasites and Vectors*, **2011**, 4, 52	4	47
85	LeishVet guidelines for the practical management of canine leishmaniosis. *Parasites and Vectors*, **2011**, 4, 86	4	393
84	Successful treatment of canine cutaneous leishmaniasis using radio-frequency induced heat (RFH) therapy. *American Journal of Tropical Medicine and Hygiene*, **2012**, 87, 261-3	3.2	1
83	Prognostic analytes in dogs with Leishmania infantum infection living in a non-endemic area. **2012**, 171, 399		16
82	Efficacy of combined therapy with liposome-encapsulated meglumine antimoniate and allopurinol in treatment of canine visceral leishmaniasis. **2012**, 56, 2858-67		44
81	The development and clinical evaluation of second-generation leishmaniasis vaccines. **2012**, 30, 134-41		78
80	Monitoring the reverse to normal of clinico-pathological findings and the disease free interval time using four different treatment protocols for canine leishmaniosis in an endemic area. **2012**, 93, 843-7		14
79	Effect of probiotic administration on the immune response: a systematic review of experimental models in rats. **2012**, 55, 685-694		3
78	Canine leishmaniosis: in vitro efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against clinical strains of Leishmania infantum. *Parasitology Research*, **2012**, 110, 2509-13	2.4	11
77	Clinicopathological study of canine transmissible venereal tumour in leishmaniotic dogs. **2012**, 53, 323-7		11
76	Association between article citation rate and level of evidence in the companion animal literature. **2012**, 26, 252-8		8
75	One-year clinical and parasitological follow-up of dogs treated with marbofloxacin for canine leishmaniosis. **2012**, 186, 245-53		18
74	In vitro susceptibility to antimonials and amphotericin B of Leishmania infantum strains isolated from dogs in a region lacking drug selection pressure. **2012**, 187, 386-93		18
73	Treatment of demodicosis in dogs: 2011 clinical practice guidelines. *Veterinary Dermatology*, **2012**, 23, 86-96, e20-1	1.8	67

72	Prognosis and monitoring of leishmaniasis in dogs: a working group report. **2013**, 198, 43-7		40
71	Treatment of canine leishmaniosis with aminosidine at an optimized dosage regimen: a pilot open clinical trial. **2013**, 192, 91-7		14
70	The Role of Reservoirs: Canine Leishmaniasis. **2013**, 45-64		4
69	Animal Health Markets and Opportunities: Companion Animal Landscape. **2013**, 15-46		1
68	Cytokine and nitric oxide patterns in dogs immunized with LBSap vaccine, before and after experimental challenge with Leishmania chagasi plus saliva of Lutzomyia longipalpis. **2013**, 198, 371-81		17
67	Chemotherapy of Leishmaniasis: A Veterinary Perspective. **2013**, 17-35		3
66	Variation of proteinuria in dogs with leishmaniasis treated with meglumine antimoniate and allopurinol: a retrospective study. **2013**, 49, 231-6		25
65	Data collection to characterise the impact of canine leishmaniosis and modelling of the role of animals in spreading Leishmania infantum within the European Union. **2014**, 11, 466E		1
64	Use of a recombinant cysteine proteinase from Leishmania (Leishmania) infantum chagasi for the Immunotherapy of canine visceral Leishmaniasis. *PLoS Neglected Tropical Diseases*, **2014**, 8, e2729	4.8	14
63	Failure of Miltefosine Treatment in Two Dogs with NaturalLeishmania infantumInfection. **2014**, 2014, 1-6		4
62	Conducting systematic reviews of intervention questions II: Relevance screening, data extraction, assessing risk of bias, presenting the results and interpreting the findings. **2014**, 61 Suppl 1, 39-51		29
61	Activity of Thymus capitellatus volatile extract, 1,8-cineole and borneol against Leishmania species. **2014**, 200, 39-49		38
60	Leishmaniosis. **2014**, 713-726		3
59	An update on the diagnosis and treatment of canine leishmaniosis caused by Leishmania infantum (syn. L. chagasi). **2014**, 202, 425-35		45
58	A systematic review of the efficacy of prophylactic control measures for naturally-occurring canine leishmaniosis, part I: vaccinations. **2014**, 117, 7-18		27
57	A systematic review of the efficacy of prophylactic control measures for naturally occurring canine leishmaniosis. Part II: topically applied insecticide treatments and prophylactic medications. **2014**, 117, 19-27		21
56	First study on efficacy and tolerability of a new alkylphosphocholine molecule (oleylphosphocholine-OlPC) in the treatment of canine leishmaniosis due to Leishmania infantum. *Parasitology Research*, **2014**, 113, 157-64	2.4	12
55	Management of canine leishmaniosis in endemic SW European regions: a questionnaire-based multinational survey. *Parasites and Vectors*, **2014**, 7, 110	4	24

54	An immune-modulating diet increases the regulatory T cells and reduces T helper 1 inflammatory response in Leishmaniosis affected dogs treated with standard therapy. **2015**, 11, 295		19
53	Scientific Opinion on canine leishmaniosis. **2015**, 13, 4075		20
52	Unresponsiveness of Experimental Canine Leishmaniosis to a New Amphotericin B Formulation. **2015**, 2015, 1-13		2
51	[Leishmania infantum induced bone lesions in a dog]. **2016**, 44, 278-82		1
50	Adverse urinary effects of allopurinol in dogs with leishmaniasis. **2016**, 57, 299-304		15
49	Current status on prevention and treatment of canine leishmaniasis. **2016**, 227, 98-114		63
48	Pustular dermatitis in dogs affected by leishmaniosis: 22 cases. *Veterinary Dermatology*, **2016**, 27, 9-e4	1.8	4
47	Vaccination against canine leishmaniosis increases the phagocytic activity, nitric oxide production and expression of cell activation/migration molecules in neutrophils and monocytes. **2016**, 220, 33-45		12
46	Insights on adaptive and innate immunity in canine leishmaniosis. **2017**, 144, 95-115		46
45	Nanostructures for Improved Antimonial Therapy of Leishmaniasis. **2017**, 419-437		2
44	Effectiveness of the sesquiterpene (-)-□bisabolol in dogs with naturally acquired canine leishmaniosis: an exploratory clinical trial. **2018**, 42, 121-130		8
43	Therapeutic vaccine of killed Leishmania amazonensis plus saponin reduced parasite burden in dogs naturally infected with Leishmania infantum. **2018**, 254, 98-104		10
42	Clinicopathological findings in sick dogs naturally infected with Leishmania infantum: Comparison of five different clinical classification systems. **2018**, 117, 18-27		28
41	The Role of Reservoirs: Canine Leishmaniasis. **2018**, 59-83		3
40	Canine visceral leishmaniasis: Diagnosis and management of the reservoir living among us. *PLoS Neglected Tropical Diseases*, **2018**, 12, e0006082	4.8	66
39	Clinical and Immunological Response in Dogs Naturally Infected by Treated with a Nutritional Supplement. *Animals*, **2019**, 9,	3.1	2
38	Evaluation of nephrotoxicity and ototoxicity of aminosidine (paromomycin)-allopurinol combination in dogs with leishmaniosis due to Leishmania infantum: A randomized, blinded, controlled study. **2019**, 206, 107768		5
37	Pathology in Practice. **2019**, 254, 813-817		

36	Leishmaniosis in dogs and cats. **2019**, 41, 5-14		1
35	Early antibody response and clinical outcome in experimental canine leishmaniasis. **2019**, 9, 18606		6
34	Allopurinol therapy provides long term clinical improvement, but additional immunotherapy is required for sustained parasite clearance, in -infected dogs. **2020**, 4, 100048		5
33	Phase I and II Clinical Trial Comparing the LBSap, Leishmune, and Leish-Tec Vaccines against Canine Visceral Leishmaniasis. **2020**, 8,		1
32	Prognostic Factors and Life Expectancy in Canine Leishmaniosis. **2020**, 7,		4
31	Comparison of Two Dosing Regimens of Miltefosine, Both in Combination With Allopurinol, on Clinical and Parasitological Findings of Dogs With Leishmaniosis: A Pilot Study. **2020**, 7, 577395		1
30	Mathematical Modelling Using Predictive Biomarkers for the Outcome of Canine Leishmaniasis upon Chemotherapy. **2020**, 8,		1
29	A randomized, blinded, controlled clinical trial comparing the efficacy of aminosidine (paromomycin)-allopurinol combination with the efficacy of meglumine antimoniate-allopurinol combination for the treatment of canine leishmaniosis due to Leishmania infantum. **2020**, 214, 107903		2
28	Therapeutic Efficacy of a Mixed Formulation of Conventional and PEGylated Liposomes Containing Meglumine Antimoniate, Combined with Allopurinol, in Dogs Naturally Infected with Leishmania infantum. **2020**, 64,		5
27	Latest trends in L. infantum infection in dogs in Spain, Part II: current clinical management and control according to a national survey of veterinary practitioners. *Parasites and Vectors*, **2020**, 13, 205	4	6
26	Canine leishmaniosis and kidney disease: Q&A for an overall management in clinical practice. **2021**, 62, E1-E19		3
25	Scientometric analysis of chemotherapy of canine leishmaniasis (2000-2020). *Parasites and Vectors*, **2021**, 14, 36	4	4
24	Vaccine as immunotherapy for leishmaniasis. **2021**, 29-46		
23	Evaluation of the effectiveness of three therapeutic protocols used in the treatment of visceral canine leishmaniosis. *International Journal for Innovation Education and Research*, **2021**, 9, 129-139	0.1	
22	Structure of the parotid gland in natural infection by Leishmania infantum in Canis familiaris. *Archives of Oral Biology*, **2021**, 124, 105077	2.8	0
21	Early onset of clinical leishmaniosis in a litter of pups with evidence of in utero transmission. *Parasites and Vectors*, **2021**, 14, 326	4	0
20	Oral Fluralaner Treatment in a Dog with Desperate Demodicosis: A Case Report. *Journal of Veterinary Clinics*, **2021**, 38, 169-173	0.1	
19	IL-10 receptor blockade controls the in vitro infectivity of Leishmania infantum and promotes a Th1 activation in PBMC of dogs with visceral leishmaniasis. *Molecular Immunology*, **2021**, 137, 20-27	4.3	1

18	Splenic immune responses during canine visceral leishmaniasis. *Veterinary Research*, **2007**, 38, 547-64	3.8	47
17	Evaluation of rK39 rapid diagnostic tests for canine visceral leishmaniasis: longitudinal study and meta-analysis. *PLoS Neglected Tropical Diseases*, **2013**, 7, e1992	4.8	51
16	Potential of Artesunate in the treatment of visceral leishmaniasis in dogs naturally infected by Leishmania infantum: Efficacy evidence from a randomized field trial. *PLoS Neglected Tropical Diseases*, **2020**, 14, e0008947	4.8	1
15	Proteinuria reduction after treatment with miltefosine and allopurinol in dogs naturally infected with leishmaniasis. *Veterinary World*, **2016**, 9, 904-8	1.7	11
14	Safety Analysis of Vaccine Used in a Randomized Canine Vaccine/Immunotherapy Trial. *American Journal of Tropical Medicine and Hygiene*, **2018**, 98, 1332-1338	3.2	9
13	Leishmania antimony resistance/ susceptibility in Algerian foci. *Open Journal of Tropical Medicine*, **2017**, 1, 024-032	0.2	0
12	Comparative evaluation of meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes and immunotherapy using an anti-canine IL-10 receptor-blocking monoclonal antibody on canine visceral leishmaniasis. *Molecular Immunology*, **2021**, 141, 70-78	4.3	0
11	A Questionnaire-Based Survey on the Long-Term Management of Canine Leishmaniosis by Veterinary Practitioners.. *Animals*, **2022**, 12,	3.1	0
10	Data_Sheet_1.docx. **2020**,		
9	Data_Sheet_1.xls. **2020**,		
8	Isolation, typing, and drug susceptibility of Leishmania (Leishmania) infantum isolates from dogs of the municipality of Embu das Artes, an endemic region for canine leishmaniasis in Brazil. *Parasitology Research*,	2.4	
7	Clinical and parasitological impact of short-term treatment using miltefosine and allopurinol monotherapy or combination therapy in canine visceral leishmaniasis. **2022**, 31,		
6	Evidence map of diagnosis, treatment, prognosis, prevention, and control in visceral leishmaniasis. **2022**, 46, 1		0
5	Canine Leishmaniasis: Update on Epidemiology, Diagnosis, Treatment, and Prevention. **2022**, 9, 387		2
4	Effectiveness of an O-Alkyl Hydroxamate in Dogs with Naturally Acquired Canine Leishmaniosis: An Exploratory Clinical Trial. **2022**, 12, 2700		0
3	Ein Update zur Leishmaniose des Hundes: Diagnostik, Therapie und Monitoring. **2022**, 50, 431-445		0
2	Leishmaniosis. **2021**, 1179-1202		0
1	In Vitro Evaluation of Aerosol Therapy with Pentamidine-Loaded Liposomes Coated with Chondroitin Sulfate or Heparin for the Treatment of Leishmaniasis. **2023**, 15, 1163		0